Impact of fluoroquinolone use on multidrug-resistant bacteria emergence

被引:10
作者
Nseir, S
Ader, F
Marquette, CH
Durocher, A
机构
[1] Ctr Hosp Reg & Univ Lille, Serv Reanimat Med, Hop A Calmette, F-59037 Lille, France
[2] Univ Lille 2, EA 3614, Lab Evaluat Med, F-59000 Lille, France
[3] Hop G Chatiliez, Serv Reanim Med & Malad Infect, F-59208 Tourcoing, France
[4] CHU Lille, Hop A Calmette, Clin Malad Resp, F-59037 Lille, France
来源
PATHOLOGIE BIOLOGIE | 2005年 / 53卷 / 8-9期
关键词
fluoroquinolones; bacterial resistance; multidrug-resistant bacteria; antibiotic treatment;
D O I
10.1016/j.patbio.2005.07.008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
During the last two decades, fluoroquinolone use has significantly increased in Europe and in the USA. This could be explained by the arrival of newer fluoroquinolones with antipneumoccal activity. Increased use of fluoroquinolones is associated with higher rates of bacterial resistance to these antibiotics. Resistance of Gram-negative bacilli to fluoroquinolones is increasing in industrialized countries. In addition, fluoroquinolone use has been identified as a risk factor for colonization and infection to methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumanni, extending-spectrum beta-lactamase producing Gram negative bacilli, and multidrug-resistant bacteria. Nosocomial infections due to multidrug-resistant bacteria are associated with higher mortality and morbidity rates. This could be related to more frequent inappropriate initial antibiotic treatment in these patients. Limiting the use of fluoroquinolones, limiting the duration of treatment with fluoroquinolones, and using appropriate dosage of these antibiotics could be suggested to reduce resistance to these antibiotics and to reduce the emergence of multidrug-resistant bacteria. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:470 / 475
页数:6
相关论文
共 55 条
[51]   Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients [J].
Weber, SG ;
Gold, HS ;
Hooper, DC ;
Karchmer, AW ;
Carmeli, Y .
EMERGING INFECTIOUS DISEASES, 2003, 9 (11) :1415-1422
[52]   Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes [J].
Wiener, J ;
Quinn, JP ;
Bradford, PA ;
Goering, RV ;
Nathan, C ;
Bush, K ;
Weinstein, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (06) :517-523
[53]   Maximizing efficacy and reducing the emergence of resistance [J].
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :37-42
[54]   Molecular epidemiology of extended-spectrum β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan [J].
Yu, WL ;
Jones, RN ;
Hollis, RJ ;
Messer, SA ;
Biedenbach, DJ ;
Deshpande, LM ;
Pfaller, AA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) :4666-4669
[55]   Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000 [J].
Zervos, MJ ;
Hershberger, E ;
Nicolau, DP ;
Ritchie, DJ ;
Blackner, LK ;
Coyle, EA ;
Donnelly, AJ ;
Eckel, SF ;
Eng, RHK ;
Hiltz, A ;
Kuyumjian, AG ;
Krebs, W ;
McDaniel, A ;
Hogan, P ;
Lubowski, TJ .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (12) :1643-1648